Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10157126 | 0.83 | HPGD (0.56) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5358931 | 0.82 | CYP2C9 (0.75) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7672594 | 0.82 | CYP2C9 (0.75) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19974889 | 0.81 | ALDH1A1 (0.51) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL196487 | 0.80 | KMT2A (0.70) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL10157134 | 0.79 | ALDH1A1 (0.61) | SMN1; SMN2RAB9AGAAHTTCYP2C9 | |
| SCHEMBL10157127 | 0.79 | CYP2C9 (0.49) | KMT2ASMN1; SMN2RAB9ACYP2C9CYP2C19 | |
| SCHEMBL4927519 | 0.79 | TGM2 (0.69) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL11054819 | 0.77 | CYP2C9 (0.57) | MEN1KMT2ARAB9ACYP2C9CYP2C19 | |
| SCHEMBL9180617 | 0.75 | ALDH1A1 (0.58) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | MEN1 2796/4885KMT2A 4025/4885SMN1; SMN2 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.